A Network Meta-Analysis of the Dose–Response Effects of Dapagliflozin on Efficacy and Safety in Adults With Type 1 Diabetes
BackgroundMost patients with type 1 diabetes (T1DM) do not reach the blood glucose goal with treatment of insulin. In our research, we intended to estimate the therapeutic effect and safety of additional different doses of dapagliflozin on insulin treatment in T1DM.MethodsWe performed direct and ind...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2022.923376/full |
| _version_ | 1818466286079836160 |
|---|---|
| author | Yinhui Li Hui Li Liming Dong Dandan Lin Lijuan Xu Pengwei Lou Deng Zang Kai Wang Li Ma |
| author_facet | Yinhui Li Hui Li Liming Dong Dandan Lin Lijuan Xu Pengwei Lou Deng Zang Kai Wang Li Ma |
| author_sort | Yinhui Li |
| collection | DOAJ |
| description | BackgroundMost patients with type 1 diabetes (T1DM) do not reach the blood glucose goal with treatment of insulin. In our research, we intended to estimate the therapeutic effect and safety of additional different doses of dapagliflozin on insulin treatment in T1DM.MethodsWe performed direct and indirect network meta-analysis using Bayesian models and graded different dosages of dapagliflozin by mixed therapy contrasts. We retrieved information from the PubMed, Embase, The Cochrane Library, Web of Science, China Biology Medicine (CBM) disc, China National Knowledge Infrastructure (CNKI), Wanfang Data, and WEIPU Data. Our research included randomized controlled trials (RCTs) including T1DM treated with insulin and additional dapagliflozin 5 mg or dapagliflozin 10 mg from January 2012 to June 2021. Thirteen RCTs with 10,701 participants were divided into three groups as below: insulin alone, dapagliflozin 5 mg + insulin, and dapagliflozin 10 mg + insulin.ResultsDapagliflozin dose-dependently exhibited reductions in glycated hemoglobin (HbA1c), total insulin daily dose (TDD), and body weight. Neither dapagliflozin 5 mg nor 10 mg could induce hypoglycemia or severe hypoglycemia. However, both doses of dapagliflozin increased the incidence of diabetic ketoacidosis (DKA) and genital infection.ConclusionsDapagliflozin 10 mg could achieve a better outcome in efficacy and could not increase the risk of hypoglycemia. Although it may induce a higher risk of DKA and genital infection, there was no significant difference between dapagliflozin 10 mg and 5 mg. Our outcomes indicate that dapagliflozin 10mg has a high reliability of being graded prior as a supplementary treatment to insulin in T1DM. |
| first_indexed | 2024-04-13T20:56:44Z |
| format | Article |
| id | doaj.art-e21de78c5cd442be85d26f773ce40cbe |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-04-13T20:56:44Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-e21de78c5cd442be85d26f773ce40cbe2022-12-22T02:30:19ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922022-07-011310.3389/fendo.2022.923376923376A Network Meta-Analysis of the Dose–Response Effects of Dapagliflozin on Efficacy and Safety in Adults With Type 1 DiabetesYinhui Li0Hui Li1Liming Dong2Dandan Lin3Lijuan Xu4Pengwei Lou5Deng Zang6Kai Wang7Li Ma8Department of Endocrine, Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University, Urumqi, ChinaDepartment of Endocrine, Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University, Urumqi, ChinaDepartment of Clinical Nutrition, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, ChinaCollege of Medical Engineering and Technology, Xinjiang Medical University, Urumqi, ChinaDepartment of Endocrine, Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University, Urumqi, ChinaDepartment of Medical Administration, Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University, Urumqi, ChinaDepartment of Endocrine, Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University, Urumqi, ChinaCollege of Medical Engineering and Technology, Xinjiang Medical University, Urumqi, ChinaDepartment of Endocrine, Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University, Urumqi, ChinaBackgroundMost patients with type 1 diabetes (T1DM) do not reach the blood glucose goal with treatment of insulin. In our research, we intended to estimate the therapeutic effect and safety of additional different doses of dapagliflozin on insulin treatment in T1DM.MethodsWe performed direct and indirect network meta-analysis using Bayesian models and graded different dosages of dapagliflozin by mixed therapy contrasts. We retrieved information from the PubMed, Embase, The Cochrane Library, Web of Science, China Biology Medicine (CBM) disc, China National Knowledge Infrastructure (CNKI), Wanfang Data, and WEIPU Data. Our research included randomized controlled trials (RCTs) including T1DM treated with insulin and additional dapagliflozin 5 mg or dapagliflozin 10 mg from January 2012 to June 2021. Thirteen RCTs with 10,701 participants were divided into three groups as below: insulin alone, dapagliflozin 5 mg + insulin, and dapagliflozin 10 mg + insulin.ResultsDapagliflozin dose-dependently exhibited reductions in glycated hemoglobin (HbA1c), total insulin daily dose (TDD), and body weight. Neither dapagliflozin 5 mg nor 10 mg could induce hypoglycemia or severe hypoglycemia. However, both doses of dapagliflozin increased the incidence of diabetic ketoacidosis (DKA) and genital infection.ConclusionsDapagliflozin 10 mg could achieve a better outcome in efficacy and could not increase the risk of hypoglycemia. Although it may induce a higher risk of DKA and genital infection, there was no significant difference between dapagliflozin 10 mg and 5 mg. Our outcomes indicate that dapagliflozin 10mg has a high reliability of being graded prior as a supplementary treatment to insulin in T1DM.https://www.frontiersin.org/articles/10.3389/fendo.2022.923376/fulldapagliflozintype 1 diabetesdosageefficacysafety |
| spellingShingle | Yinhui Li Hui Li Liming Dong Dandan Lin Lijuan Xu Pengwei Lou Deng Zang Kai Wang Li Ma A Network Meta-Analysis of the Dose–Response Effects of Dapagliflozin on Efficacy and Safety in Adults With Type 1 Diabetes Frontiers in Endocrinology dapagliflozin type 1 diabetes dosage efficacy safety |
| title | A Network Meta-Analysis of the Dose–Response Effects of Dapagliflozin on Efficacy and Safety in Adults With Type 1 Diabetes |
| title_full | A Network Meta-Analysis of the Dose–Response Effects of Dapagliflozin on Efficacy and Safety in Adults With Type 1 Diabetes |
| title_fullStr | A Network Meta-Analysis of the Dose–Response Effects of Dapagliflozin on Efficacy and Safety in Adults With Type 1 Diabetes |
| title_full_unstemmed | A Network Meta-Analysis of the Dose–Response Effects of Dapagliflozin on Efficacy and Safety in Adults With Type 1 Diabetes |
| title_short | A Network Meta-Analysis of the Dose–Response Effects of Dapagliflozin on Efficacy and Safety in Adults With Type 1 Diabetes |
| title_sort | network meta analysis of the dose response effects of dapagliflozin on efficacy and safety in adults with type 1 diabetes |
| topic | dapagliflozin type 1 diabetes dosage efficacy safety |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2022.923376/full |
| work_keys_str_mv | AT yinhuili anetworkmetaanalysisofthedoseresponseeffectsofdapagliflozinonefficacyandsafetyinadultswithtype1diabetes AT huili anetworkmetaanalysisofthedoseresponseeffectsofdapagliflozinonefficacyandsafetyinadultswithtype1diabetes AT limingdong anetworkmetaanalysisofthedoseresponseeffectsofdapagliflozinonefficacyandsafetyinadultswithtype1diabetes AT dandanlin anetworkmetaanalysisofthedoseresponseeffectsofdapagliflozinonefficacyandsafetyinadultswithtype1diabetes AT lijuanxu anetworkmetaanalysisofthedoseresponseeffectsofdapagliflozinonefficacyandsafetyinadultswithtype1diabetes AT pengweilou anetworkmetaanalysisofthedoseresponseeffectsofdapagliflozinonefficacyandsafetyinadultswithtype1diabetes AT dengzang anetworkmetaanalysisofthedoseresponseeffectsofdapagliflozinonefficacyandsafetyinadultswithtype1diabetes AT kaiwang anetworkmetaanalysisofthedoseresponseeffectsofdapagliflozinonefficacyandsafetyinadultswithtype1diabetes AT lima anetworkmetaanalysisofthedoseresponseeffectsofdapagliflozinonefficacyandsafetyinadultswithtype1diabetes AT yinhuili networkmetaanalysisofthedoseresponseeffectsofdapagliflozinonefficacyandsafetyinadultswithtype1diabetes AT huili networkmetaanalysisofthedoseresponseeffectsofdapagliflozinonefficacyandsafetyinadultswithtype1diabetes AT limingdong networkmetaanalysisofthedoseresponseeffectsofdapagliflozinonefficacyandsafetyinadultswithtype1diabetes AT dandanlin networkmetaanalysisofthedoseresponseeffectsofdapagliflozinonefficacyandsafetyinadultswithtype1diabetes AT lijuanxu networkmetaanalysisofthedoseresponseeffectsofdapagliflozinonefficacyandsafetyinadultswithtype1diabetes AT pengweilou networkmetaanalysisofthedoseresponseeffectsofdapagliflozinonefficacyandsafetyinadultswithtype1diabetes AT dengzang networkmetaanalysisofthedoseresponseeffectsofdapagliflozinonefficacyandsafetyinadultswithtype1diabetes AT kaiwang networkmetaanalysisofthedoseresponseeffectsofdapagliflozinonefficacyandsafetyinadultswithtype1diabetes AT lima networkmetaanalysisofthedoseresponseeffectsofdapagliflozinonefficacyandsafetyinadultswithtype1diabetes |